About Ibogaine Finder
An independent, citation-backed resource for anyone researching ibogaine — from patients and families to clinicians and researchers.
Our mission
Ibogaine Finder exists to fill a critical gap. As ibogaine moves from underground treatment to clinical spotlight — with 40+ active trials, FDA attention, and growing public interest following the April 2026 White House announcement — there is still no single authoritative, unbiased source of information for the people who need it most.
We built this site to be that resource. Our goal is simple: provide accurate, sourced, regularly updated information about ibogaine that helps people make informed decisions about treatment, research, and legal access.
We are not a clinic. We do not sell treatments, referrals, or supplements. We do not take affiliate fees from treatment centers. Inclusion in our clinic directory is not an endorsement — it means we have verified basic facts about a provider and presented them transparently.
Editorial standards
Citation-backed
Every factual claim links to a primary source: peer-reviewed research, FDA documents, ClinicalTrials.gov, or official government records. We do not publish claims we cannot source.
Safety-first
We lead with cardiac risks and contraindications — content that clinics and advocacy groups often downplay. Honest risk communication is non-negotiable here.
No affiliate bias
We receive no compensation from clinics, pharmaceutical companies, or any ibogaine-related business. Our only interest is accuracy.
Regularly updated
Ibogaine legal status and clinical trial data change rapidly. Country pages and drug references are reviewed and updated on a 45-day cycle. Trial data is refreshed daily from ClinicalTrials.gov.
What we cover
Research articles
Treatment, neurochemistry, clinical developments, and safety — written for a general audience with citations intact.
Drug pharmacology
Ibogaine, noribogaine, and ibogamine: mechanism of action, interactions, and legal status by country.
Condition pages
Evidence summaries for opioid addiction, depression, PTSD, and Parkinson’s, including trial results and honest gaps.
Safety protocols
Cardiac screening checklists, drug interaction warnings, contraindications, and preparation guides based on published clinical protocols.
Legal status by country
Current scheduling, regulatory exceptions, and treatment access pathways for 8+ countries, updated every 45 days.
Clinical trial tracker
Live data from ClinicalTrials.gov. Status, phase, sponsor, enrollment, and key findings for every active ibogaine study.
Clinic directory
Verified treatment centers with pricing, accreditation details, and cardiac screening standards. Hand-curated, not algorithmically scraped.
Weekly digest
FDA news, new trial registrations, and research publications — summarized weekly with links to original sources.
A note on legal status
Ibogaine is a Schedule I controlled substance in the United States. Nothing on this site constitutes medical advice, legal advice, or an endorsement of illegal activity. If you are considering ibogaine treatment, consult a qualified physician and a licensed attorney familiar with the laws in your jurisdiction.
Legal status changes. Our country pages are updated regularly, but you should always verify current regulations with a local legal professional before making any decisions based on this information.
Contact us
Have a correction, a question about our sources, or a clinic you think we should review? Use this form. We read every message, though we cannot respond to every inquiry individually.